THALYS MEDICAL TECHNOLOGY GROUP CORPORATION Thalys Medical Technology Group Corporation Share Price
Equities
603716
CNE1000030C3
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.85 CNY | +0.29% |
|
+7.70% | -38.23% |
| Sales 2021 | 2.6B 359M 29.91B | Sales 2022 | 2.31B 319M 26.57B | Capitalization | 2.12B 292M 24.34B |
|---|---|---|---|---|---|
| Net income 2021 | -49M -6.76M -564M | Net income 2022 | -154M -21.25M -1.77B | EV / Sales 2021 | 1.51 x |
| Net Debt 2021 | 1.11B 154M 12.82B | Net Debt 2022 | 1.01B 139M 11.63B | EV / Sales 2022 | 1.35 x |
| P/E ratio 2021 |
-57
x | P/E ratio 2022 |
-13.9
x | Employees | 1,474 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 75.07% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.29% | ||
| 1 week | +7.70% | ||
| Current month | -15.12% | ||
| 1 month | -18.45% | ||
| 3 months | -31.77% | ||
| 6 months | -35.01% | ||
| Current year | -38.23% |
1 week
6.14
6.88
1 month
5.978.23
Current year
5.2011.59
1 year
5.2015.98
3 years
5.2023.00
5 years
5.2023.00
10 years
5.2047.97
| Managers | Title | Age | Since |
|---|---|---|---|
Zheng Wang
CEO | Chief Executive Officer | 57 | 19/21/19 |
Yan Shen
DFI | Director of Finance/CFO | 47 | 20/23/20 |
Wei Wen
CHM | Chairman | 55 | 22/12/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Wen
CHM | Chairman | 55 | 22/12/22 |
Xiao Ming Wen
BRD | Director/Board Member | 59 | 22/12/22 |
Li Fan
BRD | Director/Board Member | 43 | 22/12/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 6.85 | +0.29% | 7,509,649 |
| 25/24/25 | 6.83 | +1.49% | 6,278,200 |
| 24/24/24 | 6.73 | +4.02% | 6,159,950 |
| 23/24/23 | 6.47 | +3.85% | 6,475,100 |
| 22/24/22 | 6.23 | -2.04% | 5,639,600 |
End-of-day quote Shanghai S.E., April 26, 2024
More quotes
Thalys Medical Technology Group Corp, formerly Thalys Medical Technology Inc, is a China-based company principally engaged in the provision of intensified distribution business and simple sales business and the research, design, manufacture and distribution of independent in vitro diagnostic products. Its product type includes purchased reagents and consumables, self-produced reagents and consumables, as well as purchased equipment. The Company mainly operates its business in domestic markets, with Hubei, Hunan, Jiangsu, Henan and Shanghai province as its major markets.
Calendar
27/04/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -38.23% | 181M | |
| -3.41% | 9.4B | |
| -3.90% | 1.39B | |
| -7.38% | 1.18B | |
| -18.42% | 857M | |
| +0.48% | 470M | |
| +3.62% | 437M | |
| -49.68% | 360M | |
| -24.72% | 333M | |
| -2.42% | 212M |
- Stock Market
- Equities
- 603716 Stock
